Sexual health peptides

Kisspeptin vs PT-141

Comparing Kisspeptin and PT-141 across evidence, dosing, mechanisms, and research areas.

vs
Category
hormone
sexualhealth
Molecular weight
5863 g/mol
1025.21 g/mol
Half-life
KP-54: ~28 minutes (IV); KP-10: ~4 minutes (IV)
~2.7 hours
Admin routes
intravenoussubcutaneous
subcutaneousintranasal
Research areas
Reproductive endocrinologyIVF/fertility treatmentHypothalamic amenorrheaPuberty initiationHypogonadismDiabetes/metabolic regulation
Hypoactive sexual desire disorder (HSDD)Female sexual dysfunctionErectile dysfunctionMale sexual arousal disordersMelanocortin system pharmacology
Typical dosing
1–12800 mcg · Variable — single bolus or pulsatile infusion depending on indication · Acute (single dose for IVF trigger) or short-term (days to weeks)
500–2000 mcg · As needed (45 min before activity, max 1 dose/24 hrs) · As needed, max 8 doses/month per FDA labeling
FDA status
Not FDA-approved. Investigational — multiple Phase 2 trials for IVF oocyte maturation and reproductive disorders.
FDA-approved as Vyleesi (bremelanotide, 2019) for premenopausal HSDD in women
WADA status
Not currently listed
Not explicitly listed as prohibited
PubMed studies
3,749
114